

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT			Attorney Docket No.: 11823-004920US		Application No.: Unassigned 09/618380	
			Applicant: J. YUN TSO		Filing Date: July 18, 2000	
			Group: Unassigned		1/2	

Reference Designation		U.S. PATENT DOCUMENTS				ATTACH TO 1.5 Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<u>LS</u> 1	4,444,878	April 1984	Paulus	—	—	
<u>LS</u> 2	4,658,019	April 1987	King et al.			
<u>LS</u> 3	4,661,586	April 1987	Levy et al.			
<u>LS</u> 4	4,676,980	June 1987	Segal et al.			
<u>LS</u> 5	4,714,681	December 1987	Reading			
<u>LS</u> 6	4,724,213	February 1988	Epstein			
<u>LS</u> 7	4,831,117	May 1989	Uckun			
<u>LS</u> 8	4,861,589	August 1989	Ju			
<u>LS</u> 9	4,892,824	January 1990	Skaletsky	—	—	
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
<u>LS</u> 10	WO90/07861A	July 26, 1990	PCT	—	—	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
<u>LS</u>	Bowie et al., Science, 247:1306-1310 (1990).					
<u>LS</u> 11	Brissinck et al., "Bispecific antibodies in lymphoma," Intern. Rev. Immunol., 10:187-194 (1993).					
<u>LS</u> 12	Burgess et al., J. Cell Bio., 111:2129-2138, (1990).					
<u>LS</u> 13	Fitzer-Schiller, The Washington Post, p. D3 (Jan. 19, 1993).					
<u>LS</u> 14	R. Gingrich et al., "Identification and characterization of a new surface membrane antigen found predominantly on malignant b lymphocytes," Blood, 75 (12) :2375-2387 (June 15, 1990).					
<u>LS</u> 15	M. Gravelle et al., "The targeting of cd4 ⁺ t lymphocytes to a b cell lymphoma," J. Immunol., 142(11):4079-4084 (June 1, 1989).					
<u>LS</u> 16	Gregoriadis et al., Trends in Biotech., 11:440-442 (1993).					
<u>LS</u> 17	Harris et al., Trends in Biotech., 11:42-44 (1993).					
<u>LS</u> 18	Jung et al., "Induction of cytotoxicity in resting human t lymphocytes bound to tumor cells by antibody heteroconjugates," Proc. Nat. Acad. Sci. USA, 84: 4611-4615 (July 1987).					
<u>LS</u> 19	Kung et al., "Monoclonal antibodies defining distinctive human t cell surface antigens," pp. 347-349 (October 19, 1979).					
<u>LS</u> 20	Lanzavecchia et al., "The use of hybrid hybridomas to target human cytotoxic to lymphocytes," Eur. J. Immunol., 17:105-111 (1987).					
<u>LS</u> 21	Lazar et al., Mol. and Cell Biol., 8:1247-1252 (1988).					
EXAMINER		DATE CONSIDERED 2/16/02				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No.: 11823-004920US	Application No.: Unassigned
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		Applicant: J. YUN TSO	09/618380
		Filing Date: July 18, 2000	Group: Unassigned 7/2
Reference Designation			Page 2
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
<u>124</u> 22	Manherimer-Lory et al., J. Exp. Med., 174:1639-1652 (1991).		
<u>125</u> 23	S. Moller et al., "Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human t lymphocytes," Cancer Immunol. Immunother., 33:210-216 (1991).		
<u>126</u> 24	T. Nitta et al., "Bispecific f(ab') ₂ monomer prepared with anti-cd3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human t cells," Eur. J. Immunol, pp. 1437-1441 (1989).		
<u>127</u> 25	Oshimi et al., "Increased lysis of patient cd10-positive leukemic cells by t cells coated with anti-cd3 fab' antibody cross-linked to anti-cd10 fab' antibody," Blood, 77(5):1044-1049 (March 1, 1991).		
<u>128</u> 26	Segal et al., "Targeting of cytotoxic cells with heterocrosslinked antibodies," Cancer Investigation, 6(1):83-92 (1988).		
<u>129</u> 27	Songsivilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease," Clin. Exp. Immunol., 79:315-321 (1990).		
<u>130</u> 28	Staerz et al., "Hybrid antibodies can target sites for attach by t cells," Nature, 314:628-631 (April 18, 1995).		
<u>131</u> 29	Staerz et al., "Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector t-cell activity," Proc. Natl. Acad. Sci. USA, 83:1453-1457 (March 1986).		
<u>132</u> 30	Tao, J. of Immunol., 143:2595-2601 (1989)		
<u>133</u> 31	Thorpe, Trends in Biotech., 11:40-42 (1993).		
<u>134</u> 32	Titus et al., "Human t cells targeted with anti-t3 cross-linked to antitumor antibody prevent tumor growth in nude mice," J. Immunol., 138(11):4018-4022 (June 1, 1987).		
<u>135</u> 33	G. Weiner et al., "Bispecific anti-idiotypic/anti-cd3 antibody therapy of murine b cell lymphoma," J. Immunol. 147:4035-4044 (December 1991).		
EXAMINER		DATE CONSIDERED 7/16/02	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.